类风湿关节炎的病理生理及生物学治疗进展

　　参 考 文 献

　　1,Fox DA.The role of T cells in the immunopathogenesis of rheumatoid arthritis.Athritis Rheum,1997,40:598-609.

　　2,Arend WP.The pathophysiology and treatment of rheumatiod arth-ritis.Athritis Rheum,1997,40:595-597.

　　3,Jawaheer D,Thomson W,MacGregor AJ,et al.Homozygosity for the HLA-DR shared epitope contributes the highest risk for rheumatoid arthritis concordance in identical twins.Arthritis Rheum,1994,37:681-686.

　　4,Goungh A,Faint J,Salmon M,et al.Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome.Arthritis Rheum,1994,37:1166-1170.

　　5,Moreland LW,Pratt PW,Mays MD,et al.Double-blind,placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody,cM-T412,in rheumatoid arthritis patients receiving concomitant methotrexate.Arthritis Rheum,1995,38:1581-1588.

　　6,van der Lubbe PA,Dijkmans BAC,Markusse HM,et al.A randomized,double-blind,placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.Arthritis Rheum,1995,38:1097-1106.

　　7,Moreland LW,Morgan EE,Adamson TC,et al.T cell receptor peptide vaccination in rheumatoid arthritis.Arthritis Rheum,1998,41:1919-1929.

　　8,Fiocco U,Cozzi L,Cozzi E.Treatment of rheumatoid arthritis by murine antiidiotypic monoclonal antibodies to a syngeneic anti-HLA class Ⅱ monoclonal antibody.Br J Rheunatol,1991,30:90-94.

　　9,Paratt W,Heck L,Moreeland L,et al.Safety and immunogenecity of a single intramuscular injection of a synthetic HLA-DR4/1-peptide vaccine with alum adjuvant in rheumatoid arthritis patients (abstract).Arth

　　10,Baumgartner S,Moreland LW,Schiff MH,et al.Double-blind,pla-cebo controlled trial of tumor nectosis factor receptor fusion protein (TNF:Fc) in active rheumatoid arthritis (abstract).J Invest Med,1996,44:235A.

　　11,Campoin GV,Lebsack ME,Lookabaugh J,et al.Dose-rang and dose-frequency st

上一页  [1] [2] [3] [4] [5] 下一页